{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/angina/prescribing-information/ranolazine/","result":{"pageContext":{"chapter":{"id":"e5a32575-7219-5c2f-b008-229c08a61dd5","slug":"ranolazine","fullItemName":"Ranolazine","depth":2,"htmlHeader":"<!-- begin field 447e96bc-6b8f-407d-8ce8-38a8d77e50f1 --><h2>Ranolazine</h2><!-- end field 447e96bc-6b8f-407d-8ce8-38a8d77e50f1 -->","summary":"","htmlStringContent":"<!-- begin item 0fe2bf62-fcae-443c-81af-7f3d2e3f43c9 --><!-- end item 0fe2bf62-fcae-443c-81af-7f3d2e3f43c9 -->","topic":{"id":"24c3b3ba-4467-513f-abfe-8ce9696ebacf","topicId":"b8a92113-15ce-47f8-b5f2-29135fbaeb9a","topicName":"Angina","slug":"angina","lastRevised":"Last revised in November 2020","chapters":[{"id":"d037d955-219a-51cb-9b7b-d80e4698480c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5b576d3c-d1ef-5582-9049-3daf9166c674","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6cf8d028-1d6d-5b17-9009-24daa603c2ad","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"a6e68c4e-737d-529e-9f2e-1d371564e243","slug":"changes","fullItemName":"Changes"},{"id":"8b294548-958c-5d4a-994a-d658b034e0ed","slug":"update","fullItemName":"Update"}]},{"id":"c182c0dc-2d1c-56e3-9ddf-42e6c9141f36","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"1551834c-ae66-5b2c-84f5-a2d776dc7567","slug":"goals","fullItemName":"Goals"},{"id":"b81e978d-4230-5023-bc0d-fb2d054d74aa","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"3c2825f8-cb3b-5b34-9ebb-b3a46c766ad4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6995e8ae-daff-5a5e-a996-7bdceeea4732","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ce74d231-e2d6-56f8-ac25-96c7241244cc","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"472866af-8514-57e4-b1d5-e76616c0e906","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"891abedd-d2c4-5a34-8cb6-b56547b6ba9b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"122479e4-f056-5d94-8c91-9b335aabc39c","slug":"definition","fullItemName":"Definition"},{"id":"7602d977-de51-5c3e-ba00-039a782195fe","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"c395652b-1917-588c-844c-c3d57cfce9ec","slug":"complications","fullItemName":"Complications"},{"id":"6afa1096-05eb-5cd0-9f06-d62a61ee26eb","slug":"prognosis","fullItemName":"Prognosis"},{"id":"0b84b71b-1d99-58d0-a7ba-5bdb9b3f6bd2","slug":"prevalence","fullItemName":"Prevalence"}]},{"id":"77a23b35-11f3-574c-b4c0-818798961d36","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1c414f08-80ea-5957-8637-b7691da3f4ba","slug":"assessment-of-stable-chest-pain","fullItemName":"Assessment of stable chest pain"},{"id":"aa7c3bff-512c-5ada-919e-f74c0d819710","slug":"confirming-the-diagnosis","fullItemName":"Confirming the diagnosis"},{"id":"7a2866dc-7796-52e4-859a-a7d02908df33","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"9f5fa5d2-ae88-5bdd-892e-f0bc8348f1a8","slug":"awaiting-diagnostic-testing","fullItemName":"Awaiting diagnostic testing"}]},{"id":"bc614509-86f3-56fe-baa9-015bad71459b","fullItemName":"Management","slug":"management","subChapters":[{"id":"97e1a557-e962-51f0-9fd2-26ed6d619574","slug":"new-diagnosis","fullItemName":"Scenario: New diagnosis"},{"id":"244b2360-1f5d-5f3e-8685-b041b97398d3","slug":"routine-review","fullItemName":"Scenario: Routine review"},{"id":"ef455505-25b3-57d4-851c-8db39de1ca9f","slug":"poor-control-on-treatment","fullItemName":"Scenario: Poor control on treatment"}]},{"id":"d18ef561-191a-5df7-a1f7-ef2d79106a0d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"813aebe7-14a8-557c-bac0-87a6cfe91c34","slug":"nitrates","fullItemName":"Nitrates"},{"id":"a1a4269f-60e8-5f82-938f-f4224de056ff","slug":"ivabradine","fullItemName":"Ivabradine"},{"id":"b276b003-d2f8-5a9d-ab8e-71924285102d","slug":"calcium-channel-blockers","fullItemName":"Calcium-channel blockers"},{"id":"e5a32575-7219-5c2f-b008-229c08a61dd5","slug":"ranolazine","fullItemName":"Ranolazine"},{"id":"ec1ac1aa-2520-5cda-877d-07f3ed8d3453","slug":"beta-blockers","fullItemName":"Beta-blockers"},{"id":"7261389f-2f16-563e-96b2-2543a8a4ee17","slug":"nicorandil","fullItemName":"Nicorandil"}]},{"id":"11c1f888-ca90-5be7-a7a1-2c8d7b44961c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"3669e04b-2ce6-595d-b4cb-e5abcb213a1e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"283f72a3-a414-5e7f-9f58-d86340ba7348","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"58238f70-829d-5fd5-bea6-4b71b01a6633","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"985e0900-f162-5892-a6ae-ee6a677babb1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d892adf9-3736-5e8b-a845-d4cb6ce084b7","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c0c74471-a5d7-52eb-bf37-6b038917dce3","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"157e1fd8-63b8-5cc6-a4ad-44ae83612fe9","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d18ef561-191a-5df7-a1f7-ef2d79106a0d","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"de4bac80-8e92-597e-ba31-00f0d8ebada3","slug":"dose-titration","fullItemName":"Dose and titration","depth":3,"htmlHeader":"<!-- begin field aa77a44e-3c45-451e-8567-a165167be8c7 --><h3>Dose and titration</h3><!-- end field aa77a44e-3c45-451e-8567-a165167be8c7 -->","summary":"","htmlStringContent":"<!-- begin item 7aeb79af-c81b-4d37-857e-3870fd1ec172 --><!-- begin field 56b7652d-06b3-4ee6-aa50-987a5808b671 --><ul><li>The initial dose of ranolazine is 375 mg twice a day.</li><li>After 2–4 weeks increase the dose to 500 mg twice a day.</li><li>If the person is still experiencing symptoms of angina, and is tolerating ranolazine, increase the dose to a maximum of 750 mg twice a day.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016i</a>]</p><!-- end field 56b7652d-06b3-4ee6-aa50-987a5808b671 --><!-- end item 7aeb79af-c81b-4d37-857e-3870fd1ec172 -->","subChapters":[]},{"id":"e4c57f24-0b30-5a8a-abaf-6881316467b7","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 95c80243-3f90-406a-b128-55a42b1640da --><h3>Adverse effects</h3><!-- end field 95c80243-3f90-406a-b128-55a42b1640da -->","summary":"","htmlStringContent":"<!-- begin item f957d728-ba5c-46ad-b21e-1afbf7f653e3 --><!-- begin field a8879881-8563-4648-b3e2-bfe79a02fd44 --><ul><li>Common adverse effects include:<ul><li>Constipation, nausea, vomiting.</li><li>Dizziness, headache.</li><li>Asthenia.</li></ul></li><li>Uncommon adverse effects include:<ul><li>Anorexia, decreased appetite, dehydration.</li><li>Anxiety, insomnia, hallucination.</li><li>Lethargy, syncope, hypoaesthesia, somnolence, tremor, postural dizziness, paresthesia.</li><li>Blurred vision, visual disturbance, diplopia.</li><li>Hot flush, hypotension.</li><li>Dyspnoea, cough, epistaxis.</li><li>Abdominal pain, dry mouth, dyspepsia, flatulence, stomach discomfort.</li><li>Pruritus, hyperhydrosis.</li><li>Muscle cramp.</li><li>Dysuria, haematuria, chromaturia.</li></ul></li><li> Rare adverse effects include: hyponatraemia, disorientation, amnesia, gait disturbances, angio-oedema, allergic dermatitis, acute renal failure, erectile dysfunction, and myoclonus.</li><li>Adverse effects tend to occur more frequently in older people (over 75 years), people with a body weight or 60 kg or less, and in those with renal impairment.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016i</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2020b</a>]</p><!-- end field a8879881-8563-4648-b3e2-bfe79a02fd44 --><!-- end item f957d728-ba5c-46ad-b21e-1afbf7f653e3 -->","subChapters":[]},{"id":"7f849e55-2e40-5b33-968f-c00837c683ab","slug":"cautions-contraindications","fullItemName":"Cautions and contraindications","depth":3,"htmlHeader":"<!-- begin field 2148fb96-7918-458d-96eb-2079a7c68a11 --><h3>Cautions and contraindications</h3><!-- end field 2148fb96-7918-458d-96eb-2079a7c68a11 -->","summary":"","htmlStringContent":"<!-- begin item 503d6d9d-8497-46ee-a542-87febea4c33d --><!-- begin field 090da990-4ec0-4dce-a268-609d5f7522cd --><ul><li><strong>Ranolazine is contraindicated in:</strong><ul><li>Severe renal impairment (avoid if creatinine clearance is less than 30 mL/min/1.73m<sup>2</sup>).</li><li>Moderate or severe hepatic impairment.</li><li>People who are also taking a potent CYP3A4 enzyme inhibitor (such as azole antifungals, macrolide antibiotics, and protease inhibitors). For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/angina/prescribing-information/ranolazine/#drug-interactions\">Drug interactions</a>.</li><li>People who are also taking Class Ia (e.g. quinidine) or Class III antiarrhythmics (e.g. sotalol), other than amiodarone.</li><li>Pregnancy, and mothers who are breastfeeding<strong>.</strong></li></ul></li><li><strong>Caution is advised in people aged 75 years or over, and people with: </strong><ul><li>Moderate to severe chronic heart failure (NYHA Class III–IV).</li><li>Hepatic impairment. </li><li>Mild to moderate renal impairment (creatinine clearance 30–80 mL/min).</li><li>Low body weight — 60 kg or less. </li><li>A history of congenital or a family history of long QT syndrome, anyone with known acquired QT interval prolongation, and anyone treated concomitantly with drugs affecting the QT interval. For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/angina/prescribing-information/ranolazine/#drug-interactions\">Drug interactions</a>.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016i</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">BNF 72, 2016</a>]</p><!-- end field 090da990-4ec0-4dce-a268-609d5f7522cd --><!-- end item 503d6d9d-8497-46ee-a542-87febea4c33d -->","subChapters":[]},{"id":"adc549d9-2357-5596-9501-b7f53c697425","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field bb2f7de8-8120-4dbc-8875-d889c54786a0 --><h3>Drug interactions</h3><!-- end field bb2f7de8-8120-4dbc-8875-d889c54786a0 -->","summary":"","htmlStringContent":"<!-- begin item 5c40c66a-55d8-498a-a466-d7c982d9be6a --><!-- begin field 9fcc59de-34d1-4a4f-bd9a-9188e1bc3b11 --><ul><li><strong>CYP3A4 inhibitors </strong>(such as azole antifungals, macrolide antibiotics, and protease inhibitors) increase the plasma levels of ranolazine. Concomitant use is contraindicated.<ul><li>Grapefruit juice is also a potent CYP3A4 inhibitor and the person should be advised to avoid grapefruit juice and grapefruit-containing products.</li><li>Moderate inhibitors (such as diltiazem and verapamil) should be given concomitantly with caution. The dose ranolazine may need to be reduced.</li></ul></li><li><strong>CYP3A4 inducers</strong> (such as carbamazepine, rifampicin, phenytoin, phenobarbital and St John's wort) decrease the plasma levels of ranolazine. Concomitant use is contraindicated.</li><li><strong>Statins</strong> (such as atorvastatin, simvastatin, lovastatin) — ranolazine may increase plasma concentrations. Dose adjustment of statins may be required. For more information, see the CKS topic <a class=\"topic-reference external-reference\" href=\"/topics/lipid-modification-cvd-prevention/\">Lipid modification - CVD prevention</a>.</li><li><strong>Immunosuppressants</strong> (tacrolimus, ciclosporin, sirolimus, everolimus) — ranolazine may increase plasma levels. Monitor blood levels and adjust dose accordingly. </li><li><strong>QT interval prolongation</strong> — concomitant administration of other drugs that prolong the QT interval may increase the risk of ventricular arrhythmias. These include antihistamines (astemizole, mizolastine), class I antiarrhythmics (for example quinidine), class III antiarrhythmics (for example sotalol), erythromycin, and tricyclic antidepressants.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">Baxter and Preston, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016i</a>]</p><!-- end field 9fcc59de-34d1-4a4f-bd9a-9188e1bc3b11 --><!-- end item 5c40c66a-55d8-498a-a466-d7c982d9be6a -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}